The multi-functional role of sphingosylphosphorylcholine

Progress in Lipid Research

Volumn 47, Issue 1, 2008, Pages 62-75

  Nixon, Graeme F ^a   Mathieson, Fiona A ^a   Hunter, Irene ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Calcium; Cardiovascular; Epidermis; Inflammation; Sphingosine 1 phosphate; Sphingosylphosphorylcholine

Indexed keywords

CALCIUM; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 18; LIPID; LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE A2; PHOSPHOLIPASE D; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RHO KINASE; RYANODINE RECEPTOR; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSYLPHOSPHORYLCHOLINE; TUMOR NECROSIS FACTOR ALPHA;

BLOOD VESSEL; BRAIN; CELL TYPE; HEART; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LIPID METABOLISM; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKIN;

ANIMALS; BLOOD VESSELS; CALCIUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNE SYSTEM; MYOCARDIUM; NEURONS; PHOSPHORYLCHOLINE; SIGNAL TRANSDUCTION; SKIN; SPHINGOSINE;

EID: 36749072778     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plipres.2007.11.001     Document Type: Review

References (143)

1. Okazaki T., Bell R.M., and Hannun Y.A. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J Biol Chem 264 (1989) 19076-19080
2. 3 pituitary cells. J Biol Chem 262 (1987) 16759-16762
3. Ramstedt B., and Slotte J.P. Membrane properties of sphingomyelins. FEBS Lett 531 (2002) 33-37
4. Kolesnick R.N. Sphingomyelin and derivatives as cellular signals. Prog Lipid Res 30 (1991) 1-38
5. Hannun Y.A., and Bell R.M. The sphingomyelin cycle: a prototypic sphingolipid signaling pathway. Adv Lipid Res 25 (1993) 27-41
6. Kolesnick R.N. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 110 (2002) 3-8
7. Goni F.M., and Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett 531 (2002) 38-46
8. Machesini N., and Hannun Y.A. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 82 (2004) 27-44
9. Tani M., Ito M., and Igarashi Y. Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. Cell Signal 19 (2007) 229-237
10. Andrieu-Abadie N., and Levade T. Sphingomyelin hydrolysis during apoptosis. Biochim Biophys Acta 1585 (2002) 126-134
11. Riboni L., Viani P., Bassi R., Prinetti A., and Tettamanti G. The role of sphingolipids in the process of signal transduction. Prog Lipid Res 36 (1997) 153-195
12. Kolesnick R., and Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 22 (2003) 5897-5906
13. Gulbins E. Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol Res 47 (2003) 393-399
14. Alemany R., van Koppen C.J., Danneberg K., Ter Braak M., and Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 374 (2007) 413-428
15. Spiegel S., and Milstien S. Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem 282 (2007) 2125-2129
16. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 15 (2004) 513-520
17. Yatomi Y. Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr Pharm Des 12 5 (2006) 575-587
18. Rosen H., and Goetzl E.J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5 (2005) 560-570
19. McVerry B.J., and Garcia J.G. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal 17 (2005) 131-139
20. Spiegel S., and Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 277 (2002) 25851-25854
21. Sanchez T., and Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 92 (2004) 913-922
22. Anliker B., and Chun J. Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 15 (2004) 457-465
23. Pyne S., and Pyne N. Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther 88 (2000) 115-131
24. Hla T., and Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem 265 (1990) 9308-9313
25. Lee M.J., Van Broklyn J.R., Thangada S., Liu C.H., Hand A.R., Menzeleev R., et al. Sphingosine-1-phosphate as a ligand for the G protein coupled receptor EDG-1. Science 279 (1998) 1552-1555
26. Okazak H., Ishizaka N., Sakurai T., Kurokawa K., Goto K., Kumada M., et al. Molecular-cloning of a novel putative G-protein-coupled receptor expressed in the cardiovascular-system. Biochem Biophys Res Commun 190 (1993) 1104-1109
27. Yamaguchi F., Tokuda M., Hatase O., and Brenner S. Molecular cloning of the novel human G protein-coupled receptor (GPCR) gene mapped on chromosome 9. Biochem Biophys Res Commun 227 (1996) 608-614
28. Graler M.H., Bernhardt G., and Lipp M. EDG6, a novel G-protein coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics 53 (1998) 164-169
29. Im D.S., Heise C.E., Ancellin N., O'Dowd B.F., Shei G.J., Heavens R.P., et al. Characterization of a novel sphingosine 1-phosphate receptor, EDG-8. J Biol Chem 275 (2000) 14281-14286
30. Meyer Zu Heringdorf D., and Jakobs K.H. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 1768 (2007) 923-940
31. Ancellin N., and Hla T. Differential pharmacological properties and signal transduction of sphingosine 1-phosphate receptors EDG-1, EDG-3 and EDG-5. J Biol Chem 274 (1999) 18997-19002
32. 12 families of heterotrimeric G proteins. J Biol Chem 274 (1999) 27351-27358
33. Peters S.L., and Alewijnse A.E. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 7 (2007) 186-192
34. Alewijnse A.E., Peters S.L., and Michel M.C. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol 143 (2004) 666-684
35. Argraves K.M., Obeid L.M., and Hannun Y.A. Sphingolipids in vascular biology. Adv Exp Med Biol 507 (2002) 439-444
36. Yatomi Y., Ruan F., Hakomori S., and Igarashi Y. Sphingosine 1-phosphate: a platelet-activating sphingolipid released from stimulated human platelets. Blood 86 (1995) 193-202
37. Yatomi Y., Yamamura S., Ruan F., and Igarashi Y. Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid. J Biol Chem 272 (1997) 5291-5297
38. Kobayashi N., Nishi T., Hirata T., Kihara A., Sano T., Igarashi Y., et al. Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. J Lipid Res 47 (2006) 614-621
39. Yatomi Y., Igarashi Y., Yang L., Hisano N., Qi R., Asazuma N., et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem (Tokyo) 121 (1997) 969-973
40. Murata N., Sato K., Kon J., Tomura H., and Okajima F. Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. Anal Biochem 282 (2000) 115-120
41. Coussin F., Scott R.H., Wise A., and Nixon G.F. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 91 (2002) 151-157
42. Murata N., Sato K., Kon J., Tomura H., Yanagita M., Kuwabara A., et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 352 (2000) 809-815
43. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?. Biochim Biophys Acta 23 1582 (2002) 132-137
44. Sachinidis A., Kettenhofen R., Seewald S., Gouni-Berthold I., Schmitz U., Seul C., et al. Evidence that lipoproteins are carriers of bioactive factors. Arterioscler Thromb Vasc Biol 19 (1999) 2412-2421
45. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 276 (2001) 31780-31785
46. Meyer Zu Heringdorf D., Himmel H.M., and Jakobs K.H. Sphingosylphosphorylcholine-biological functions and mechanisms of action. Biochim Biophys Acta 1582 (2002) 178-189
47. Dawson R.M. The reported occurrence of sphingosylphosphorylcholine in animal tissues. Biochem J 68 (1958) 357-360
48. Desai N.N., and Spiegel S. Sphingosylphosphorylcholine is a remarkably potent mitogen for a variety of cell lines. Biochem Biophys Res Commun 181 (1991) 361-366
49. Liliom K., Sun G., Bunemann M., Virag T., Nusser N., Baker D.L., et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J 355 (2001) 189-197
50. Rodriguez-Lafrasse C., and Vanier M.T. Sphingosylphosphorylcholine in Niemann-Pick disease brain: accumulation in type A but not in type B. Neurochem Res 24 (1999) 199-205
51. Murata Y., Ogata J., Higaki Y., Kawashima M., Yada Y., Higuchi K., et al. Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency?. J Invest Dermatol 106 6 (1996) 1242-1249
52. Hara J., Higuchi K., Okamoto R., Kawashima M., and Imokawa G. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 115 (2000) 406-413
53. Sekiguchi K., Yokoyama T., Kurabayashi M., Okajima F., and Nagai R. Sphingosylphosphorylcholine induces a hypertrophic growth response through the mitogen-activated protein kinase signaling cascade in rat neonatal cardiac myocytes. Circ Res 85 (1999) 1000-1008
54. Nofer J.R., Fobker M., Hobbel G., Voss R., Wolinska I., Tepel M., et al. Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry 39 (2000) 15199-15207
55. Nofer J.R., and Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 15 (2005) 265-271
56. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158 (2002) 227-233
57. Tokumura A., Majima E., Kariya Y., Tominaga K., Kogure K., Yasuda K., et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277 (2002) 39436-39442
58. Clair T., Aoki J., Koh E., Bandle R.W., Nam S.W., Ptaszynska M.M., et al. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63 (2003) 5446-5453
59. Nam S.W., Clair T., Kim Y.S., McMarlin A., Schiffmann E., Liotta L.A., et al. Autotaxin (NPP-2), a metastasis-enhancing mitogen, is an angiogenic factor. Cancer Res 61 (2001) 6938-6944
60. Cui P., Tomsig J.L., McCalmont W.F., Lee S., Becker C.J., Lynch K.R., et al. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Bioorg Med Chem Lett 17 (2007) 1634-1640
61. Tornquist K., and Ekokoski E. Effect of sphingosine derivatives on calcium fluxes in thyroid FRTL-5 cells. Biochem J 299 (1994) 213-218
62. 2+ mobilization by sphingosylphosphorylcholine and galactosylsphingosine in HL60 leukemia cells. Implications of GTP-binding protein-coupled receptors for lysosphingolipids. J Biol Chem 270 (1995) 26332-26340
63. Van Koppen C.J., Meyer Zu Heringdorf D., Zhang C., Laser K.T., and Jakobs K.H. A distinct G(i) protein-coupled receptor for sphingosylphosphorylcholine in human leukemia HL-60 cells and human neutrophils. Mol Pharmacol 49 (1996) 956-961
64. An S., Bleu T., Huang W., Hallmark O.G., Coughlin S.R., and Goetzl E.J. Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett 417 (1997) 279-282
65. Okamoto H., Takuwa N., Yatomi Y., Gonda K., Shigematsu H., and Takuwa Y. EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16. Biochem Biophys Res Commun 260 (1999) 203-208
66. Parrill A.L., Sardar V.M., and Yuan H. Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands. Semin Cell Dev Biol 15 (2004) 467-476
67. 2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem 273 (1998) 27104-27110
68. 2+ signaling induced by sphingosylphosphorylcholine and sphingosine 1-phosphate via distinct mechanisms in rat glomerular mesangial cells. Kidney Int 54 (1998) 1470-1483
69. Orlati S., Porcelli A.M., Hrelia S., and Rugolo M. Sphingosylphosphorylcholine and sphingosine-1-phosphate mobilize cytosolic calcium through different mechanisms in human airway epithelial cells. Cell Calcium 23 (1998) 387-394
70. Xu Y., Zhu K., Hong G., Wu W., Baudhuin L.M., Xiao Y., et al. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol 2 (2000) 261-267
71. Zhu K., Baudhuin L.M., Hong G., Williams F.S., Cristina K.L., Kabarowski J.H., et al. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J Biol Chem 276 (2001) 41325-41335
72. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., and Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293 (2001) 702-705
73. Ludwig M.G., Vanek M., Guerini D., Gasser J.A., Jones C.E., Junker U., et al. Proton-sensing G-protein-coupled receptors. Nature 425 (2003) 93-98
74. Bektas M., Barak L.S., Jolly P.S., Liu H., Lynch K.R., Lacana E., et al. The G protein-coupled receptor GPR4 suppresses ERK activation in a ligand-independent manner. Biochemistry 42 (2003) 12181-12191
75. Mogi C., Tomura H., Tobo M., Wang J.Q., Damirin A., Kon J., et al. Sphingosylphosphorylcholine antagonizes proton-sensing ovarian cancer G-protein-coupled receptor 1 (OGR1)-mediated inositol phosphate production and cAMP accumulation. J Pharmacol Sci 99 2 (2005) 160-167
76. Xu Y., Zhu K., Hong G., Wu W., Baudhuin L.M., Xiao Y., et al. Retraction: sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol 8 3 (2006) 299
77. Zhu K., Baudhuin L.M., Hong G., Williams F.S., Cristina K.L., Kabarowski J.H., et al. Retraction: sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J Biol Chem 280 (2005) 43280
78. Seuwen K., Ludwig M.G., and Wolf R.M. Receptors for protons or lipid messengers or both?. J Recept Signal Transduct Res 26 (2006) 599-610
79. Jeon E.S., Song H.Y., Kim M.R., Moon H.J., Bae Y.C., Jung J.S., et al. Sphingosylphosphorylcholine induces proliferation of human adipose tissue-derived mesenchymal stem cells via activation of JNK. J Lipid Res 47 (2006) 653-664
80. 2+ in vascular smooth muscle: effects on CREB activation. Br J Pharmacol 147 (2006) 351-359
81. Desai N.N., Carlson R.O., Mattie M.E., Olivera A., Buckley N.E., Seki T., et al. Signaling pathways for sphingosylphosphorylcholine-mediated mitogenesis in Swiss 3T3 fibroblasts. J Cell Biol 121 (1993) 1385-1395
82. 2+ oscillations in rat pancreatic acinar cells. J Biol Chem 268 (1993) 12353-12358
83. Tornquist K., and Ekokoski E. Effect of sphingosine derivatives on calcium fluxes in thyroid FRTL-5 cells. Biochem J 299 (1994) 213-218
84. Dettbarn C., Betto R., Salviati G., Sabbadini R., and Palade P. Involvement of ryanodine receptors in sphingosylphosphorylcholine-induced calcium release from brain microsomes. Brain Res 669 (1995) 79-85
85. 2+ mobilization by sphingosylphosphorylcholine and galactosylsphingosine in HL60 leukemia cells. Implications of GTP-binding protein-coupled receptors for lysosphingolipids. J Biol Chem 270 (1995) 26332-26340
86. Betto R., Teresi A., Turcato F., Salviati G., Sabbadini R.A., Krown K., et al. Sphingosylphosphocholine modulates the ryanodine receptor/calcium-release channel of cardiac sarcoplasmic reticulum membranes. Biochem J 322 (1997) 327-333
87. Meyer Zu Heringdorf D., Niederdraing N., Neumann E., Frode R., Lass H., Van Koppen C.J., et al. Discrimination between plasma membrane and intracellular target sites of sphingosylphosphorylcholine. Eur J Pharmacol 354 (1998) 113-122
88. 2+-dependent pathway. Am J Physiol 275 (1998) C1255-C1263
89. 2+ signaling in MC3T3-E1 osteoblastic cells. J Bone Miner Res 16 (2001) 2035-2042
90. Kye K.C., Chae E.K., Piao Y.J., Park S., Park J.K., Kim C.D., et al. Signaling events during induction of plasminogen activator inhibitor-1 expression by sphingosylphosphorylcholine in cultured human dermal fibroblasts. J Invest Dermatol 122 (2004) 1365-1371
91. Jeon E.S., Kang Y.J., Song H.Y., Im D.S., Kim H.S., Ryu S.H., et al. Sphingosylphosphorylcholine generates reactive oxygen species through calcium-, protein kinase Cdelta- and phospholipase D-dependent pathways. Cell Signal 17 (2005) 777-787
92. 2+ entry. Cardiovasc Res 68 (2005) 56-64
93. 2+ release-mediating protein from endoplasmic reticulum. Proc Natl Acad Sci USA 93 (1996) 1993-1996
94. Cavalli A.L., O'Brien N.W., Barlow S.B., Betto R., Glembotski C.C., Palade P.T., et al. Expression and functional characterization of SCaMPER: a sphingolipid-modulated calcium channel of cardiomyocytes. Am J Physiol Cell Physiol 284 (2003) C780-C790
95. 2+ channel activated by sphingosylphosphocholine. Biochem J 362 (2002) 183-189
96. Seufferlein T., and Rozengurt E. Sphingosylphosphorylcholine activation of mitogen-activated protein kinase in Swiss 3T3 cells requires protein kinase C and a pertussis toxin-sensitive G protein. J Biol Chem 270 (1995) 24334-24342
97. Bitar K.N., and Yamada H. Modulation of smooth muscle contraction by sphingosylphosphorylcholine. Am J Physiol 269 (1995) G370-G377
98. Higuchi K., Kawashima M., Ichikawa Y., and Imokawa G. Sphingosylphosphorylcholine is a melanogenic stimulator for human melanocytes. Pigment Cell Res 16 (2003) 670-678
99. Kleger A., Busch T., Liebau S., Prelle K., Paschke S., Beil M., et al. The bioactive lipid sphingosylphosphorylcholine induces differentiation of mouse embryonic stem cells and human promyelocytic leukaemia cells. Cell Signal 19 (2007) 367-377
100. Jeon E.S., Kang Y.J., Song H.Y., Woo J.S., Jung J.S., Kim Y.K., et al. Role of MEK-ERK pathway in sphingosylphosphorylcholine-induced cell death in human adipose tissue-derived mesenchymal stem cells. Biochim Biophys Acta 1734 (2005) 25-33
101. 2+-sensitization of vascular smooth muscle contraction: possible involvement of rho-kinase. FEBS Lett 482 (2000) 85-90
102. Zhu M.J., Kim C.D., Kwon Y.B., Kye K.C., Chen Y.Y., Lee W.H., et al. Induction of connective tissue growth factor expression by sphingosylphosphorylcholine in cultured human skin fibroblasts. Exp Dermatol 14 (2005) 509-514
103. 2+ sensitization of coronary artery contraction mediated by a sphingosylphosphorylcholine-Rho-kinase pathway. Circ Res 91 (2002) 953-960
104. Bunemann M., Liliom K., Brandts B.K., Pott L., Tseng J.L., Desiderio D.M., et al. A novel membrane receptor with high affinity for lysosphingomyelin and sphingosine 1-phosphate in atrial myocytes. EMBO J 15 (1996) 5527-5534
105. Himmel H.M., Meyer Zu Heringdorf D., Graf E., Dobrev D., Kortner A., Schuler S., et al. Evidence for Edg-3 receptor-mediated activation of I(K.ACh) by sphingosine-1-phosphate in human atrial cardiomyocytes. Mol Pharmacol 58 (2000) 449-454
106. 2+ and voltage dependence of cardiac ryanodine receptor channel block by sphingosylphosphorylcholine. Pfluger Arch 445 (2003) 665-673
107. Robert P., Tsui P., Laville M.P., Livi G.P., Sarau H.M., Bril A., et al. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol 33 (2001) 1589-1606
108. Bischoff A., Czyborra P., Fetscher C., Meyer Zu Heringdorf D., Jakobs K.H., and Michel M.C. Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br J Pharmacol 130 (2000) 1871-1877
109. Watterson K.R., Ratz P.H., and Spiegel S. The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal 17 (2005) 289-298
110. Bischoff A., Czyborra P., Meyer Zu Heringdorf D., Jakobs K.H., and Michel M.C. Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol 130 (2000) 1878-1883
111. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
112. Kluk M.J., and Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res 89 (2001) 496-502
113. Boguslawski G., Grogg J.R., Welch Z., Ciechanowicz S., Sliva D., Kovala A.T., et al. Migration of vascular smooth muscle cells induced by sphingosine 1-phosphate and related lipids: potential role in the angiogenic response. Exp Cell Res 274 (2002) 264-274
114. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 4 (2004) 372-377
115. Sack M. Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacol Ther 94 (2002) 123-135
116. Mogami K., Mizukami Y., Todoroki-Ikeda N., Ohmura M., Yoshida K., Miwa S., et al. Sphingosylphosphorylcholine induces cytosolic Ca(2+) elevation in endothelial cells in situ and causes endothelium-dependent relaxation through nitric oxide production in bovine coronary artery. FEBS Lett 457 (1999) 375-380
117. Sun L., Xu L., Henry F.A., Spiegel S., and Nielsen T.B. A new wound healing agent-sphingosylphosphorylcholine. J Invest Dermatol 106 (1996) 232-237
118. Boguslawski G., Lyons D., Harvey K.A., Kovala A.T., and English D. Sphingosylphosphorylcholine induces endothelial cell migration and morphogenesis. Biochem Biophys Res Commun 272 (2000) 603-609
119. Piao Y.J., Lee C.H., Zhu M.J., Kye K.C., Kim J.M., Seo Y.J., et al. Involvement of urokinase-type plasminogen activator in sphingosylphosphorylcholine-induced angiogenesis. Exp Dermatol 14 (2005) 356-362
120. Nofer J.R., Levkau B., Wolinska I., Junker R., Fobker M., von Eckardstein A., et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276 (2001) 34480-34485
121. Nofer J.R., Geigenmuller S., Gopfert C., Assmann G., Buddecke E., and Schmidt A. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem Biophys Res Commun 310 (2003) 98-103
122. Schmidt A., Geigenmuller S., Volker W., and Buddecke E. The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt → NF-kappaB signalling pathways in human vascular endothelial cells. Basic Res Cardiol 101 (2006) 109-116
123. Nofer J.R., van der Giet M., Tolle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113 (2004) 569-581
124. Gouni-Berthold I., and Sachinidis A. Possible non-classic intracellular and molecular mechanisms of LDL cholesterol action contributing to the development and progression of atherosclerosis. Curr Vasc Pharmacol 2 (2004) 363-370
125. Liu Y., Wada R., Yamashita T., Mi Y., Deng C.X., Hobson J.P., et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106 (2000) 951-961
126. Jeon E.S., Moon H.J., Lee M.J., Song H.Y., Kim Y.M., Bae Y.C., et al. Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-beta-dependent mechanism. J Cell Sci 119 (2006) 4994-5005
127. Suhr K.B., Tsuboi R., Seo E.Y., Piao Y.J., Lee J.H., Park J.K., et al. Sphingosylphosphorylcholine stimulates cellular fibronectin expression through upregulation of IL-6 in cultured human dermal fibroblasts. Arch Dermatol Res 294 (2003) 433-437
128. Gailit J., and Clark R.A.F. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol 6 (1994) 717-725
129. Igarashi A., Okochi H., Bradham M.D., and Grotendorst G.R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 4 (1993) 637-645
130. Okamoto R., Arikawa J., Ishibashi M., Kawashima M., Takagi Y., and Imokawa G. Sphingosylphosphorylcholine is upregulated in the stratum corneum of patients with atopic dermatitis. J Lipid Res 44 (2003) 93-102
131. Holleran W.M., Takagi Y., and Uchida Y. Epidermal sphingolipids: metabolism, function, and roles in skin disorders. FEBS Lett 580 (2006) 5456-5466
132. Imokawa G., Takagi Y., Higuchi K., Kondo H., and Yada Y. Sphingosylphosphorylcholine is a potent inducer of intercellular adhesion molecule-1 expression in human keratinocytes. J Invest Dermatol 112 (1999) 91-96
133. Griffith C.E.M., Voorhees J.J., and Nockoloff B.J. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 20 (1989) 617-626
134. Huang W.C., and Chueh S.H. Calcium mobilization from the intracellular mitochondrial and nonmitochondrial stores of the rat cerebellum. Brain Res 718 (1996) 151-158
135. 2+ mobilization from rat brain microsomes. J Lipid Mediat Cell Signal 14 (1996) 303-311
136. +-exchange mechanism in GH4C1 cells. Eur J Biochem 248 (1997) 394-400
137. Furukawa A, Kita K, Toyomoto M, Fujii S, Inoue S, Hayashi K, et al. Production of nerve growth factor enhanced in cultured mouse astrocytes by glycerophospholipids, sphingolipids, and their related compounds. Mol Cell Biochem 2007 [Epub ahead of print].
138. MacLennan A.J., Carney P.R., Zhu W.J., Chaves A.H., Garcia J., Grimes J.R., et al. An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci 14 (2001) 203-209
139. Simonaro C.M., Desnick R.J., McGovern M.M., Wasserstein M.P., and Schuchman E.H. The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet 71 (2002) 1413-1419
140. McGovern M.M., Aron A., Brodie S.E., Desnick R.J., and Wasserstein M.P. Natural history of type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology 66 (2006) 228-232
141. Chiulli N., Codazzi F., Di Cesare A., Gravaghi C., Zacchetti D., and Grohovaz F. Sphingosylphosphocholine effects on cultured astrocytes reveal mechanisms potentially involved in neurotoxicity in Niemann-Pick type A disease. Eur J Neurosci 26 (2007) 875-881
142. Jin Y., Damaj B.B., and Maghazachi A.A. Human resting CD16-, CD16+ and IL-2-, IL-12-, IL-15- or IFN-alpha-activated natural killer cells differentially respond to sphingosylphosphorylcholine, lysophosphatidylcholine and platelet-activating factor. Eur J Immunol 35 (2005) 2699-2708
143. Ceballos A., Sabatte J., Nahmod K., Martinez D., Salamone G., Vermeulen M., et al. Sphingosylphosphorylcholine activates dendritic cells, stimulating the production of interleukin-12. Immunology 121 (2007) 328-336